Who Paid My Doc
Eric Dahlquist
Infectious Disease Iowa City, IA Doctor of Osteopathy
NPI 1740925254 CMS profile 11688740
200 Hawkins Dr, Iowa City, IA 52242
General payments
$125
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Eric Dahlquist of Iowa City, IA is reported in the CMS Open Payments database as having received $125 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 27th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $125 | 1 |
Beside peers
- Eric Dahlquist
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Eric Dahlquist were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Eric Dahlquist | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $0 | $171 | $57–$787 | $160 |
| 2024 | $125 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
95
Drug cost
$722
Branded share of claims
24.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pantoprazole Sodium | Generic | 15 | $261 | |
| Atorvastatin Calcium | Generic | 31 | $169 | |
| Amlodipine Besylate | Generic | 13 | $98 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 12 | $97 | |
| Sertraline Hcl | Generic | 13 | $81 | |
| Metformin Hcl Er Metformin Hcl | Brand | 11 | $15 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Infectious Disease in Iowa
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Iowa
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.